TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo standard of care biopsy for suspected prostate cancer, or re-biopsy with prior negative systemic biopsy or restaging biopsy in patients with known prostate cancer on active surveillance~Exclusion Criteria:~* History of myocardial infarction within 6 months of the enrollment~* Active infection (except mild upper respiratory infections)~* Active prostatitis~* Non-prostate cancers currently on treatment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (18F-FMAU PET/CT) (Type: EXPERIMENTAL): Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of Early Medical Adrenalectomy for D0.5 Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the prostate Stage IV (D0.5; no evidence of disease on CT or bone scan after testicular androgen ablation) PSA progression after testicular androgen ablation with or without antiandrogen therapy Progression is defined as at least 2 consecutive rising PSA levels (drawn at least 2 weeks apart) with a greater than 50% rise above the last nadir level (arbitrary PSA at least 2 ng/dL)~PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other medical conditions that would increase risk Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: See Disease Characteristics Greater than 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide) No prior aminoglutethimide or ketoconazole for prostate cancer Continuation of primary testicular androgen suppression (i.e., LHRH analog) required Radiotherapy: Not specified Surgery: Not specified Other: No concurrent terfenadine, astemizole, cisapride, or other medicines known to interact with ketoconazole

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone with Ketoconazole (Type: ACTIVE_COMPARATOR): Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
- Hydrocortisone with Aminoglutethimide (Type: ACTIVE_COMPARATOR): Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CML in chronic phase who have failed to achieve or have lost an adequate response to IM. For the purpose of this trial this will be defined as a lack of any cytogenetic response after 6 months of therapy or lack of major cytogenetic response after 12 months of therapy with IM. Patients that have lost their major or complete cytogenetic response will also be eligible. Patients who show a sustained increase in breakpoint cluster region gene (BCR)-Abelson gene (ABL)/ABL \[BCR-ABL/ABL\] ratio of \>/= 1-log confirmed in at least two consecutive Polymerase Chain Reaction (PCR) analyses (at least one month apart from each other) will also be eligible.~2. \*continued from above: Patients with stable molecular response defined as 2 consecutive PCR-positive results (no more than 1/2 log improvement) will also be eligible. Patients must be taking stable dose of IM for at least 3 months before study enrollment, and recovered from all toxicities related to IM, to grade 0-1.~3. Patients should be in complete or partial hematological remission, including white blood count (WBC) \</=20 x 10(9)/L, and platelets \</= 600 x 10(9)/L.~4. Eastern Cooperative Oncology Group (ECOG) scale performance status of 2 or less.~5. Age greater than 18 years of age since disease is extremely rare in younger age groups.~6. Adequate liver (total bilirubin of less than 2 times and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of less than 2 times upper limits of normal), and renal function (creatinine of less than 2 times upper limit of normal).~7. Signed informed consent form.~8. Negative pregnancy test in women of childbearing age.~9. Negative hepatitis B and C screening blood tests.~Exclusion Criteria:~1. Serious intercurrent medical illnesses or active infections requiring parenteral antibiotics that would interfere with the ability of the patient to carry out the treatment program.~2. Female patients who are pregnant or breast-feeding.~3. Patients taking steroids, or those anticipated to receive steroids during the trial therapy.~4. Prior bone marrow transplant.~5. Known positivity for human immunodeficiency virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TALL-104 + IM (Type: EXPERIMENTAL): TALL-104 cells and imatinib mesylate (IM) therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PWS confirmed by chromosome analysis~* Ages 5 years to 21 years~* BMI for age ≥ (greater-than or equal to)85th percentile~* Written informed consent and assent obtained and willingness to comply with the study schedule and procedures~* Free T4, Thyroid stimulating hormone (TSH) values in the normal range (either endogenous or with thyroxine replacement)~Exclusion Criteria:~* Patients with any other clinically significant disease that would have an impact on body composition, including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders~* Concomitant use of an investigational drug or Octreotide in the past year~* Use of steroids for longer than 7 days within the past 30 days

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: EXPERIMENTAL): Octreotide to be administered by subcutaneous injection three times daily while on study
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to be administered by subcutaneous injection three times daily while on study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 70 years or older at time of diagnosis~* No restrictions on gender or ethnicity~* Ability and willingness to make follow up appointments~* Pathologic diagnosis of rectal cancer~* Presentation could be symptomatic or asymptomatic~* T1-T3 primary rectal adenocarcinoma as determined on TRUS, CT, or MRI pelvis~* Peri-rectal node positive allowed~* Inability to tolerate radical surgery, as judged by geriatric oncology or surgeon and tumor board OR patient refusal of surgery~* Inability to receive chemoradiation therapy, defined as concurrent chemotherapy and radiation doses of 45-50.4 Gy, as judged by radiation, medical, or geriatric oncology~* Patients with dementia eligible if Health Care Proxy (HCP) is available and supportive of follow up schedule~Exclusion Criteria:~* Age under 70 years of age~* Ability and desire to receive definitive surgical intervention~* Ability and desire to receive concurrent chemoradiation therapy

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elderly rectal cancer patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BRIDGE Device for Post-operative Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria:~  * ≥18 years of age but \<70 years of age~ * Actively listed for isolated liver transplantation~ * Subject or legally authorized representative able to sign informed consent~ * Not currently treated with opioids or any medications that may interact with opioids~ * English speaking~ * Willing and able to participate and consent to this study~Exclusion Criteria:~* Diagnosis of acute liver failure or primary sclerosing cholangitis (PSC)~* Anticipated that the subject will require a new roux-en-y hepaticojejunostomy~* Current use of opioid use or other substance abuse.~* Chronic pain disorders~* Need for regional anesthesia (regional nerve blocks or epidurals)~* Adhesive allergy/sensitivity~* Subject admitted to the ICU at the time of transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
- Group 2 (Type: NO_INTERVENTION): Subjects will receive the standard of care pain control analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Decision to treat with DMF must precede enrollment~2. Ability to understand the purpose and risk of the study and provide authorization for the use of protected health information in accordance with the monitoring agency~3. Men or women 18 years of age or older at the time of informed consent~4. Naïve to DMF or fumaric acid esters~5. Confirmed diagnosis of a relapsing form of multiple sclerosis as verified by the Principal Investigator~Exclusion Criteria:~1. Unable to unwilling to comply with study requirements as outlined in the informed consent~2. Known active malignancies or any other major comorbidities that, in the opinion of the Investigator, would affect the outcome of the study~3. Pregnant or breastfeeding or likely to become pregnant during the course of the study. Women of child-bearing potential must practice an acceptable form of birth control~4. Previous treatment with dimethyl fumarate~5. Past history of GI malignancy, gastric ulceration refractory to medical resolution, history of gastrectomy. At the discretion of the PI, resolved GI ulceration, gastroesophageal reflux will not be exclusionary~6. Known sensitivity or allergic reaction to peanuts, simethicone, or loperamide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: NO_INTERVENTION): Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS \>6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
- Treatment Arm (Type: ACTIVE_COMPARATOR): Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with first presentation of acute pericarditis (both idiopathic and post pericardiectomy)~* Patients diagnosed according to accepted clinical findings: 2 of the 4 following criteria: chest pain, pericardial friction rub, ECG changes typical for pericarditis and/or pericardial effusion.~* Patients over the age of 18 years~Exclusion Criteria:~* Patient with Uncontrolled Diabetes (as defined as hyperglycaemia \>300mg/dl at presentation or HBA1C\>9% (if known))~* Patients with a known allergy to steroid therapy~* Patient with a known allergy to NSAID therapy~* Patients with a known contraindication to colchicine therapy~* Pregnancy or lactating women~* Patients with systemic fungal infection~* Patients with a known pericardial effusion of tuberculous, purulent, or neoplastic causes~* Patients with chronic steroid use~* Patients with a known rheumatological disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Therapy (Type: ACTIVE_COMPARATOR): Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (\<70kg) or 0.5mg twice daily (\>70kg) for 3 months
- Dexamethasone therapy (Type: EXPERIMENTAL): Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (\<70kg) or 0.5mg twice daily (\>70kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Strategies for Primarily Generalized Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primarily generalized colorectal cancer diagnosed by pathology or typical appearance on x-ray or at endoscopy and where there is uncertainty regarding best treatment strategy~Exclusion Criteria:~* Patients not willing to participate or unable to sign informed consent.~* Patients with other malignancy with metastatic potential~* Patients where synchronous resection of primary tumour and metastases is planned~* Patients not fit for chemotherapy or surgery~* Patients with locally unresectable primary tumours~* Patients with symptoms from primary colorectal tumour necessitating resection

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traditional strategy (Type: ACTIVE_COMPARATOR): First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
- Alternative strategy (Type: ACTIVE_COMPARATOR): First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months of age to 17 years of age (not yet 18)~* Male or female~* English or Spanish speaking~* Normal airway (Mallampati Classification )~* American Society of Anesthesiology Physical Status Classification I or II~* Elective surgical procedure expected to last at least 45 minutes in length~* Written informed consent/assent for participation given by the parent legal guardian and subject (if applicable)~Exclusion Criteria:~* \< 6 months of age, \> 17 years of age~* Difficult airway (Mallampati Classification)~* History of previous difficult intubation, suspected abnormal airway: \*micrognathia~  * facial trauma~ * airway tumor~ * epiglottitis~ * retropharyngeal abscess~ * foreign body, etc.~ * Scheduled for non-elective, emergent OR procedure~ * Parent, legal guardian, or subject is unavailable or unwilling to consent for study participation

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
- Cisatracurium (Type: ACTIVE_COMPARATOR): Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* ≥ 2 years and ≤ 21 years of age at the time of study entry~* Scheduled to receive chemotherapy for:~* Newly diagnosed:~* Non-rhabdo soft tissue sarcomas, scheduled to receive chemotherapy, as well as intermediate or high-risk rhabdomyosarcoma, any stage osteosarcoma and any stage Ewing's sarcoma~* Intermediate or high-risk neuroblastoma~* Wilms' tumor (Stage III/IV)~* Hepatoblastoma (Stage III/IV)~* Germ cell tumors (Stage III/IV)~* Brain tumors, including medulloblastoma, PNET and ependymomas~* AML~* Relapsed/recurrent disease (any patient)~* Able to register and randomize within 28 days of starting chemotherapy (registration /randomization and start of study agent may occur at anytime up to and including Day 28 after the initiation of chemotherapy)~EXCLUSION CRITERIA:~* ≥ 29 days after starting chemotherapy~* Documented history of unintended weight loss ≥ 5% presumed secondary to cancer within 3 months of study entry~* Currently taking cyproheptadine HCl (or have taken cyproheptadine HCl within 3 weeks of study registration)~* History of anorexia nervosa or bulimia~* Taking other appetite-stimulating medications, i.e. dronabinol (Marinol) during the past three weeks.~* Initiation of other appetite enhancing agents, including steroids prescribed for the intent of weight gain, i.e. Megace. Note: Other forms of nutrition therapies, e.g. appetite-stimulating medications, TPN or enteral tube feedings are not allowed during this study.~* Children receiving steroids for \>7 days as part of their cancer treatment regimen are excluded from participation. However, intermittent steroid use in an antiemetic regimen is allowed during the study~* Receiving monoamine oxidase (MAO) inhibitors, procarbazine, fluoxetine (Prozac), or paroxetine (Paxil)~* Diagnosed with glaucoma, cystic fibrosis, inflammatory bowel disease, or GI/GU obstruction~* Allergy to cyproheptadine HCl~* Females of childbearing age must not be pregnant.~* Female patients who are lactating must agree to stop breast-feeding.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm I cyproheptadine hydrochloride (Type: EXPERIMENTAL): Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
- Arm II placebo (Type: PLACEBO_COMPARATOR): Patients receive an oral placebo twice daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues